Skip to main navigation Skip to search Skip to main content

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

  • the EMBODY Investigator Group

Research output: Contribution to journal › Article › peer-review

209   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Neuroscience

Pharmacology, Toxicology and Pharmaceutical Science